In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Yuta YamadaDivision of Experimental Hematology, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-5103-8047 Jinjing YangDivision of Stem Cell and Molecular Medicine, Centre for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akiho Saiki-TsuchiyaDivision of Stem Cell and Molecular Medicine, Centre for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0009-0001-9775-0822 Yuji WatanabeMedical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shuhei KoideDivision of Stem Cell and Molecular Medicine, Centre for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yuriko SorimachiDepartment of Stem Cell Biology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Yu FukudaDivision of Experimental Hematology, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-6182-540X Kenta SumiyamaDepartment of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Aichi, Japan.ORCID 0000-0001-8785-5439 Hiroshi SagaraMedical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Keiyo TakuboDepartment of Stem Cell Biology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-1736-7592 Atsushi IwamaDivision of Stem Cell and Molecular Medicine, Centre for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-9410-8992 Masayuki YamashitaDivision of Experimental Hematology, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA. masayuki.yamashita@stjude.org.ORCID 0000-0001-9459-4329 Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MBasic and Translational Research Training in Pediatric Classical HematologyT32HL176447 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SHANNON L MCKINNEY-FREEMAN · 2025 to 2026
$505kJapan Agency for Medical Research and Development (AMED) 25bm1123063Japan Agency for Medical Research and Development (AMED) JP20gm1210011MEXT | Japan Society for the Promotion of Science (JSPS) 20K17395MEXT | Japan Society for the Promotion of Science (JSPS) 22H03101MEXT | Japan Society for the Promotion of Science (JSPS) 23H02707MEXT | Japan Society for the Promotion of Science (JSPS) 24H00640MEXT | Japan Society for the Promotion of Science (JSPS) 25H01435MEXT | Japan Society for the Promotion of Science (JSPS) 25K22629NCI NIH HHS P30 CA021765NHLBI NIH HHS T32 HL176447
6 · The paper itselfAbstract
Hematopoietic stem cells (HSCs) survive many types of cellular stress but often lose their regenerative and lymphopoietic capacities as a result. Such functional decline also occurs with age, and dysfunctional HSCs with impaired mitochondria accumulate during aging. However, the molecular link between HSC stress response and age-related functional decline remains poorly understood. Here we show that multiple stress responses converge on the RIPK3-MLKL axis to induce age-related changes in HSCs. The necroptosis effector MLKL is readily activated by inflammation and replication stress and accumulates in HSC mitochondria. Consequently, activated MLKL does not cause cell death but impairs HSC self-renewal and lymphoid differentiation. Such MLKL-mediated functional decline also occurs in HSCs during organismal aging, with activated MLKL primarily mediating age-related mitochondrial damage and reduced glycolytic flux. Collectively, our results establish the RIPK3-MLKL axis as a key mediator of HSC aging and identify a necroptosis-independent role of MLKL in mitochondrial damage.
Indexed as
Cellular SenescenceHematopoietic Stem CellsMitochondriaProtein KinasesAnimalsMiceMice, Inbred C57BLMice, KnockoutNecroptosisReceptor-Interacting Protein Serine-Threonine KinasesMLKL protein, mouseProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesRipk3 protein, mouse
Identifiers
PMID41942424
PMCPMC13053712
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390